| Literature DB >> 30350331 |
Sabrina Croce1, Tom Lesluyes2,3,4,5, Lucile Delespaul3,4, Benjamin Bonhomme1, Gaëlle Pérot1, Valérie Velasco1, Laetitia Mayeur1, Flora Rebier1, Houda Ben Rejeb1, Frédéric Guyon6, W Glenn McCluggage7, Anne Floquet8, Denis Querleu3,6, Camille Chakiba8, Mojgan Devouassoux-Shisheboran9, Eliane Mery5, Laurent Arnould10, Gerlinde Averous11, Isabelle Soubeyran1, Sophie Le Guellec4,5, Frédéric Chibon4,5.
Abstract
Mutations of CTNNB1 have been implicated in tumorigenesis in many organs. However, tumors harboring a CTNNB1 translocation are extremely rare and this translocation has never been reported in a uterine mesenchymal neoplasm. We report a novel translocation t(2;3)(p25;p22) involving the GREB1 (intron 8) and CTNNB1 (exon 3) in a uterine tumor resembling ovarian sex cord tumor (UTROSCT), which exhibited extrauterine metastasis. The translocation detected by RNA-sequencing was validated by RT-PCR, and resulted in nuclear expression of β-catenin. Juxtapositioning with GREB1, which is overexpressed in response to estrogens, resulted in overexpression of a truncated and hypophosphorylated nuclear β-catenin in the primary and recurrent tumors. This accumulation of nuclear β-catenin results in a constitutive activation of the Wnt/β-catenin signaling pathway with a major oncogenic effect. The CTNNB1 gene fusion, promoted by an estrogen-responsive gene (GREB1), could be a potential driver of tumorigenesis in this case and a therapeutic target with adapted inhibitors. RT-PCR and immunohistochemistry performed on 11 additional UTROSCTs showed no CTNNB1 fusion transcript or nuclear β-catenin immunoreactivity.Entities:
Keywords: UTROSCT; cytogenetic; molecular biology; pathology; translocation
Mesh:
Substances:
Year: 2019 PMID: 30350331 DOI: 10.1002/gcc.22694
Source DB: PubMed Journal: Genes Chromosomes Cancer ISSN: 1045-2257 Impact factor: 5.006